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Effects of arginine vasopressin and 1 -desamino-8-D 
arginine vasopressin on forearm vasculature of healthy 
subjects and patients with a V2 receptor defect
Angenita F. van Lieburg, Nine V.A.M. Knoers*, 
Leo A.H. Monnens and Paul Smitst
Objectives: To assess which vasopressin receptor subtype mediates the vasodilation 
occurring in response to arginine vasopressin and 1-desamino-8-D (DD)-argtnine 
vasopressin and whether nitric oxide is involved in these effects.
Materials and methods: Vasoactive effects of arginine vasopressin and DD-arginine 
vasopressin on forearm vasculature were studied in healthy subjects and in patients 
with congenital nephrogenic diabetes insipidus with a vasopressin type 2 (V2) receptor 
gene defect. Venous occlusion plethysmography was used to assess the forearm blood 
flow responses to the infusion of arginine vasopressin and its analogue into the 
brachial artery, in the presence and the absence of the nitric oxide synthase inhibitor 
L-NG-monomethyl-arginine (l-NMMA).
Results: In healthy subjects (n-10), DD-arginine vasopressin (0.1, 1 and 10 or 5,
10 and 20ng/min per dl) induced a dose-related increase in forearm biood flow, but 
did not affect forearm blood flow in the patients with nephrogenic diabetes insipidus 
(n = 3). In two healthy subjects, seven increasing doses of arginine vasopressin 
(0.25-12 ng/min per dl) induced an initial decrease in forearm blood flow and then 
a gradual increase. In one of the patients, the same arginine vasopressin doses 
produced a persistent decrease in forearm blood flow. In the healthy subjects, 
infusion of l-NMMA reduced forearm blood flow significantly (n = 10). Subsequent 
administration of DD-arginine vasopressin during l-NMMA infusion produced a slight 
reduction in the forearm blood flow increase compared with DD-arginine vasopressin 
alone, but this was significant only for the absolute forearm blood flow increase 
induced by 10 ng/min per dl in all subjects. Infusion of arginine vasopressin in the 
presence of l-NMMA did not increase forearm blood flow significantly.
Conclusions: In human forearm vasculature, extrarenal V2 receptors mediate 
the vasodilation induced by DD-arginine vasopressin or high doses of arginine 
vasopressin, whereas these receptors are not necessary for arginine vasopressin- 
induced vasoconstriction. The DD-arginine vasopressin-induced vasodilation seems 
to be mediated predominantly by a mechanism other than endothelial nitric oxide 
release, whereas arginine vasopressin-induced vasodilation seems to involve nitric 
oxide release only.
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Introduction owes its two names to its main functions: vaso-
' ---------------------------------------------- "" constriction and antidiuresis. Vasopressin type 1 (V \)
The neurohypophyseal hormone arginine vasopressin, receptors on vascular smooth muscle cells mediate the
which is also referred to as the antidiuretic hormone, vasoconstrictive action, whereas vasopressin type 2 (V2)
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receptors are involved in the antidiuretic effect exerted 
in renal collecting duct cells. A less well-known effect 
o f  arginine vasopressin is vasodilation, which has been 
found to occur in response to high local concentrations 
o f  the ho rm one  [1—5]. Attempts to assess the type of 
receptor mediating this va so dilatory action have yielded 
contradictory results, with discrepancies between in i>u>o 
and in vitro studies, among diflerent species and among 
vascular beds [6- 8]. h i vivo studies using Vj receptor 
antagonists have indicated that the vasodilation occur­
ring  in response to high doses of arginine vasopressin 
is mediated by Vo receptors [1,3,9—13], an observation 
w hich is in accord with the vasodilatory effect o f 
the V 2 receptor agonist l-desam ino-8 -U (DD)-arginine 
vasopressin [1], Furthermore, recent investigations have 
suggested a role for endothelium-derived nitric oxide 
in the vasodilator response to arginine vasopressin
[4,14-17].
In the present study, we assessed in human forearm 
vasculature which vasopressin receptor subtype mediates 
arginine vasopressin- and D D -arginine vasopressin- 
induced vasodilation by comparing the responses of 
healthy subjects w ith those o f patients with a proven 
V2 receptor defect and w hether nitric oxide is involved 
in arginine vasopressin- and DD-arginine vasopressin- 
induced vasodilation.
M a t e r i a l s  a n d  m e t h o d s
Subjects
T he study protocol was approved by the local ethical 
com m ittee o f  the University Hospital Nijmegen. All 
subjects gave w ritten informed consent.
Fifteen healthy male volunteers (aged 19—31 years) 
and three male patients with congenital nephrogenic 
diabetes insipidus (aged 21—30 years) participated in the 
study. All o f  the nephrogenic diabetes insipidus patients 
had had polyuria and polydipsia since early childhood 
and showed no antidiuretic response to DD-arginine 
vasopressin. In the three patients, D N A  sequencing 
analysis o f  the receptor gene had been performed as 
described previously [18]. In all o f the patients, point 
mutations had been detected in this gene, resulting in 
ammo acid substitutions in two o f  them  (phenylalanine 
44 to leucine and arginine 202 to cysteine, respectively) 
and introduction o f  a premature stop codon in the third 
pa:ient (arginine 337 to stop codon).
A physical examination and electrocardiography revealed 
no abnormalities in any o f  the participants. The 
experiments were perform ed after overnight fasting by 
the subjects. D uring  the 24 h preceding the experiment, 
they did no t smoke or drink beverages containing 
caffeine or alcohol. In the 2 weeks preceding the
study none o f  the healthy volunteers had taken any 
medication. One o f  the diabetes patients complied 
with a request to stop taking hydrochlorothiazide, 
amiloride and indomethacin 36 h before the start of 
the experiment, and one patient, who was taking 
hydrochlorothiazide and amiloride, continued using the 
medication. The third patient was not taking any 
medication.
<
Study design
The brachial artery o f the left arm was cannula ted, 
The experiments started after an equilibration period of 
30 min. Forearm blood flow o f  both arms was measured 
by venous occlusion mercury-in-silastic strain gauge 
plethysmography Simultaneously, circulation o f  the hand 
was arrested by inflating a cuff around the wrist. The 
forearm blood flow values obtained during the last 2 min 
o f each infusion were used for further analysis. Blood 
pressure and heart rate were recorded intra-arterially 
(Hewlett-Packard Gm bH, Böblingen, Germany).
Protocols were designed to assess the vascular response 
o f DD-arginine vasopressin and arginine vasopressin in 
healthy subjects; the vascular response to DD-arginine 
vasopressin and arginine vasopressin in nephrogenic 
diabetes insipidus patients with a VS receptor defect; and 
the effect o f  L-A/G-monomethy 1-arginine (l-NM M A) 
on DD-arginine vasopressin- and arginine vasopressin- 
induced vasodilation. One healthy subject and one 
nephrogenic diabetes insipidus patient participated in 
both the DD-arginine vasopressin and the arginine 
vasopressin experiment.
Drugs
Desmopressin-acetatehydrate (1 -desamino-8-1 )-arginine 
vasopressin, Minrin; Ferring, Malmö, Sweden; 0,4 
was diluted with 0.9% sodium chloride. Doses o f  either 
0.1, 1 and 10 or 5, 10 and 20 ng/m in per dl forearm 
volume were infused during subsequent 5-min periods. 
Arginine vasopressin (Pitressin; Parke-Davis, Berlin, 
Germany; 0.05 g/1) was diluted with 0.9% sodium 
chloride. Doses o f 0.25, 0.5, 1, 2, 4, 8 and 12 ng/min 
per dl were administered during subsequent 5-min 
periods. L-N ^-m onom ethy 1-arginine was dissolved in 
0.9%) sodium chloride and administered at a dose of 
0.1 m g/m in per dl. An L-NMMA infusion was started 
5 min before and maintained during the second infusion 
of DD-arginine vasopressin or arginine vasopressin. All 
drugs were infused intra-arterially by an automatic 
syringe infusion pump at a constant total infusion rate 
of 50 jLll/min per dl.
Statistical analysis
Paired student’s t-tests were used to evaluate the effect 
of L-NMMA 011 baseline forearm blood flow and, 
by comparison o f  changes in forearm blood flow 
from baseline, the effect o f  L-NMMA on DD-arginine 
vasopressin-induced vasodilation.
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Results
Effects of DD-arginine vasopressin and arginine 
vasopressin in healthy subjects
Infusion o f  DD-arginine vasopressin at 0.1, 1 and 
10 ng/m in per dl had no significant effect at the lowest 
dose but an increase in forearm blood flow occurred 
at the two higher doses (from 1.6 ±0.5 during saline 
infusion to 7.9 ±2 .5  m l/m in per dl at the highest dose; 
n = 3). Doses o f DD-arginine vasopressin at 5, 10 and 
20 ng/m in per dl administered to seven healthy subjects 
produced a dose-related increase in forearm blood flow 
(Table 1; Fig. 1).
Table 1. Forearm blood flow response of healthy subjects to intra- 
arterial infusion of different doses of 1-desamino-S-D-arginine vaso­
pressin (n = 7).
Dose (ng/min per dl) 
Baseline _________________________ _ ____
value 5 10 20
Forearm blood flow (ml/min per dl)
Before L-NMMA 2.3 + 0.7 6.6 ±1.3 7.7 + 1.7 10.3 + 2,5 
During L-NMMA 1.7 + 0.3 5.0±0.9 5.9 + 1.1 8.1 ±1.6
Percentage forearm blood flow 
Before L-NMMA 100 223±33 270±54 394±94 
During l-NMMA 100 228±62 272±56 423±95
Values are expressed as means±SEM. l-NMMA, administration of 
L-NG-monomethyl-arginine.
Forearm blood flow (ml/min/dl)
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Fig. 1. Forearm blood flow response to 1-desamino-8-D- 
arginine vasopressin (DDAVP) in seven healthy subjects 
(■— ■) and three patients with nephrogenic diabetes in­
sipidus with a V2 receptor defect (•-- •). Values are ex­
pressed as means ±SEM.
The administration o f increasing doses of arginine 
vasopressin (0.25-12.0 ng/m in per dl) resulted in a slight 
initial decrease in forearm blood flow, from 1.4 ±0.4  to 
1.1 ± 0 .4 m l/m in per dl, and then a gradual increase to
3.1 ± 0 .5 m l/m in  per dl at the highest dose (n =  2, Fig. 
2).
Forearm blood flow (m l/m in/dt)
Base 0.25 0.50 1.0 2,0 4.0 8,0 '12.0
A VP dose (ng/min/dl)
Fig. 2. Forearm blood flow response to arginine vasopressin 
(AVP) in two healthy subjects (B  M) and a patient with 
nephrogenic diabetes insipidus with a V2 receptor defect 
(•— • ). Values are expressed as means or means±SEM.
Effects of DD-arginine vasopressin and arginine 
vasopressin in patients with nephrogenic diabetes 
insipidus
The administration o f  D D -arg in ine  vasopressin at 5, 10 
and 20 ng /m l per dl in three patients w ith nephrogenic 
diabetes insipidus did not affect forearm blood flow (Fig. 
1). Infusion o f  the arginine vasopressin dose scheme into 
one of the patients resulted in. a decrease in forearm 
blood flow from 1.2  m l/m in  per dl during saline infusion 
to 0.4 m l/m in  per dl at the highest arginine vasopressin 
dose (Fig. 2).
Effects of l-NMMA on DD-arginine 
vasopressin- and arginine vasopressin-induced 
vasodilation in healthy subjects
D uring the 5-m in period  o f  L-N M M A  infusion pre­
ceding the second D D -arg in ine  vasopressin infusion, 
forearm blood flow decreased significantly from 2.3 ± 0 .5  
to 1.6 ± 0 .2  m l/m in  per dl (n = 1 0 , P=0.05). Subsequent 
administration o f D D -arg in ine vasopressin at 0.1, 1 and 
10m g/m in  per dl (n= 3) and 5, 10 and 20 ng /m in  per 
dl (n=7) during L -N M M A  infusion revealed a partial 
reduction in the forearm blood flow increase induced 
by DD-arginine vasopressin, w hich reached statistical 
significance for the 10-ng  dose administered to all 10 
subjects (5,7 ± 1 .0  versus 4.2 ± 0 .8  m l/m in  per dl, n = 1 0 , 
P < 0 .0 1 , Fig. 3). T he forearm blood flow increase at 
the 5-  and 20 -ng doses was not significantly reduced 
during L-NM M A. T he forearm blood flow increase as a 
percentage o f  the baseline value was not significant for 
any o f  the doses. T he  increase in forearm blood flow 
induced by a second infusion o f  D D -arginine vasopressin 
at 5 , 10 and 20 n g /m in  per dl w ithout concomitant
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L-N M M A  (n - 4 )  did not differ significantly from the 
increase during the first infusion.
DDAVP-induced increase in FB F  (m I/m in/d I)
Fig. 3: Forearm blood flow (FBF) increase from baseline as 
a result of 1 'desamino-8-D~arginine vasopressin (DDAVP) in­
fusion (10 ng/min per dl) with and without concomitant infu­
sion of L-NG-mono methyl-arginine (l-NMMA) in 10 healthy 
subjects. Means±SEM are also shown.
Administration o f  arginine vasopressin at 0.5, 4 and
12 ng /m in  per dl during an infusion of L-NMMA 
produced no significant increase in forearm blood flow
(0.8 ±0.1  at baseline versus 0.7 ±0,1 , 1.0 ± 0 .09  and
1 .2 ± 0 .2 m l/m in  per dl, respectively).
N one o f the studies showed significant changes in 
blood pressure, heart rate or forearm blood flow in the 
contralateral arm.
Discussion
Studies assessing the vaso dilatory mechanism of arginine 
vasopressin and its analogue DD-arginine vasopressin 
have yielded conflicting data. In vitro experiments 
in canine cerebral vessels and rat pulmonary artery 
and aorta suggested involvement o f Vj receptors 
[15,16.19], Similarly, in hum an in vitro studies, argi­
nine vasopressin-induced vasodilation o f  cerebral and 
mesenterial arteries was found to be independent of 
Vo receptor stimulation [19,20]. However, most in vivo 
studies provide evidence that Vo receptors are involved 
in arginine vasopressin- and D D -arginine vasopressin- 
induced vasodilation [1,3,5,9—13]. Furthermore, it has 
been postulated that the vasodilation and associated 
release o f  coagulation and fibrinolysis factors occurring 
in response to arginine vasopressin and DD-arginine 
vasopressin administration is neither mediated by V \  nor
by V2 receptors because studies in rat aortae and in 
conscious dogs have revealed an absence o f  inhibition 
both by V] and by Vo antagonists [22,23]. T he most 
plausible reason for this confusion seems to be the 
variability in the pharmacological profile o f  agonists 
and /o r antagonists that has been suggested to exist 
among species, between in vitro and in vivo studies and 
among different vascular beds [6- 8].
Hum an in vivo studies assessing the effect o f  high 
systemic doses of arginine vasopressin are scarce because 
o f the risk o f severe vasoconstriction. However, it is 
clear that no substantial increase in blood pressure 
occurs despite maintenance o f high plasma arginine 
vasopressin levels [24]. The vascular effects o f Vo 
receptor antagonists have only recently been examined 
in a hum an in vivo study, which appeared to confirm that 
in the hum an forearm V 2 receptors are involved in the 
vasodilatory effect o f arginine vasopressin [5]. However, 
these conclusions need to be considered with caution, 
because most V2 receptor antagonists show partial 
Vj receptor antagonism and their putative specificity 
has been based mainly on their aquaretic potencies 
in animals [6—8]. However, studies in patients with 
X-linked nephrogenic diabetes insipidus have provided 
convincing evidence for involvement of the V2 receptor 
in the vasodilatory actions of DD-arginine vasopressin
[25]. As a result o f  mutations in the V2 receptor gene, 
patients w ith nephrogenic diabetes insipidus lack the 
renal antidiuretic response to DD-arginine vasopressin
[26], In addition, these patients show no vasodilatory, 
coagulation or fibrinolytic responses to DD-arginine 
vasopressin, indicating that these extrarenal effects are 
normally mediated either by an extrarenal Vo receptor 
encoded by the same gene or by the renal V2 receptor,
In the present study we circumvented the restrictions 
imposed by the side effects o f  high systemic doses 
of arginine vasopressin and DD-arginine vasopressin 
and the problems caused by lack o f specificity o f V2 
receptor antagonists, by studying the vascular effects of 
arginine vasopressin and DD-arginine vasopressin in the 
human forearm both o f healthy subjects and o f patients 
with a proven V2 receptor gene defect. The absence 
of vasodilation during administration of DD-arginine 
vasopressin and high doses o f arginine vasopressin 
in nephrogenic diabetes insipidus patients proves that 
both effects are mediated by the receptor encoded by 
the V 2 receptor gene, excluding the occurrence of 
non-specific vasodilatory effects or actions mediated 
by other receptors, for instance the V \  or oxytocin 
receptor. In addition, it shows that the high selectivity 
of DD-arginine vasopressin for the renal V2 receptor 
also applies to the extrarenal Vo receptor. Moreover, 
the present study unequivocally proves that the absence 
of extrarenal response to DD-arginine vasopressin in 
patients with X-linked nephrogenic diabetes insipidus is 
a direct consequence o f an extrarenal V2 receptor defect 
and is neither caused nor influenced by their renal V2 
receptor defect.
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As in studies seeking the receptor involved in argi­
nine vasopressin- and DD-arginine vasopressin-induced 
vasodilation, attempts to determine which vasodilatory 
substance mediates this action have produced varying 
results. In vitro studies in canine cerebral vessels and 
rat aortae have suggested that nitric oxide causes 
these effects [14-16]. However, Russ and colleagues 
[14,27] observed only partial inhibition of arginine 
vasopressin-induced vasodilation by high doses of nitric 
oxide synthase inhibitors in rat lungs and provided 
evidence against involvement o f  prostaglandins and 
hyper polarizad on o f vascular smooth muscle. Moreover, 
in their in vitro study o f  human cerebral and mesenterial 
arteries, Martinez ct al. [20,21] found that release of 
nitric oxide in these vessels accounts neither for arginine 
vasopressin- nor for DD-arginine vasopressin-induced 
vasodilation.
It has been shown that the counter-regulation ob­
served in healthy humans after systemic administration 
of high doses of arginine vasopressin is abolished 
by indomethacin, suggesting that prostaglandins are 
involved in its vasodilatory effect [28]. In contrast, 
studies of arginine vasopressin-induced vasodilation in 
the human forearm by Suzuki ct ciL [2] suggested that 
prostaglandins are not involved while experiments by 
Tagawa ct a l [4] strongly implied the involvement o f 
nitric oxide. Hasunuma ct al. [29] found that vasodi­
lation after systemic DD-arginine vasopressin infusion 
was not influenced by indomethacin or propranolol 
administration; however, they did observe an increase 
in urinary 6 -keto prostaglandin F |a . We observed 
that the L-NMMA-induced reduction in DD-arginine 
vasopressin response, if any, was rather small, whereas 
the current data show, in accord with the findings by 
Tagawa ct aL [4], that L-NM M A inhibited arginine 
vasopressin-induced vasodilation almost completely
How can these observations be reconciled with the 
conclusion that arginine vasopressin and DD-arginine 
vasopressin both cause vasodilation by stimulating the 
V2 receptor? Since DD-arginine vasopressin elicited a 
threefold stronger increase in forearm blood flow than 
arginine vasopressin did, the present L-NMMA dose 
of 0.1 m g/m in per dl might not have been sufficient 
to compete with the quantity of nitric oxide released 
by DD-arginine vasopressin, whereas it is adequate 
in the case of arginine vasopressin. However, even 
with DD-arginine vasopressin at 5 ng/m in per dl, the 
inhibition was not complete and did not clearly decrease 
with higher doses of DD-arginine vasopressin.
A more plausible explanation is based on the fact that 
arginine vasopressin interacts with both Vi and V2 
receptors. The V] receptor pathway could, for instance, 
attenuate an L-NMMA-insensitive vasodilatory compo­
nent o f the V2 receptor pathway. Another possibility is 
that arginine vasopressin, because of a possible lower 
availability or affinity for the V2 receptor, initiates 
only the nitric oxide-dependent mechanisms, whereas 
DD-arginine vasopressin is capable of inducing an
additional L-NMMA-insensitive pathway [30], Insight 
into these mechanisms might be increased by the 
discovery o f  the exact location o f  the extrarenal V 2 
receptor. Although physiological evidence has now been 
obtained that these receptors exist in the hum an forearm, 
radioligand binding studies have not been able to 
confirm their presence in endothelial or vascular smooth 
muscle cells [31]. However, blood cells, especially 
monocytes, are a likely location [32,33], Furthermore, 
although the present study shows that extrarenal V2 
receptors are the product o f  the same gene as renal V2 
receptors, the possibility cannot be excluded that, as a 
result o f  alternative splicing, there is some heterogeneity 
among receptors encoded by the Vo receptor gene, 
as recently shown to be the case in the kidney [3 4 ]. 
Further research awaits the detection o f extrarenal gene 
expression o f  this gene at the messenger R N A  or protein 
level.
The present study proves that extrarenal Y 2 receptors 
in the hum an forearm m ediate the vasodilation induced 
by DD-arginine vasopressin and high doses o f  arginine 
vasopressin, whereas these receptors are not necessary for 
arginine vasopressin-induced vasoconstriction. Secondly, 
DD-arginine vasopressin-induced vasodilation seems to 
be mediated predominantly by a mechanism other 
than endothelial nitric oxide release, whereas arginine 
vasopressin-induced vasodilation seems to involve nitric 
oxide release only. Thus, despite the fact that the 
same receptor is involved, it appears that the mecha­
nisms underlying arginine vasopressin- and D D -arginine 
vasopressin-induced vasodilation are not completely 
identical.
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